MONTREAL, Aug. 20, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) applauds the work done by Muscular Dystrophy Canada and the provinces to ensure that every newborn in Canada will be screened to detect spinal muscular atrophy (SMA).
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
